Navigation Links
Study Disproves Belief That Hepatitis C Blunts HIV Drugs

Impaired immune response after antiretroviral therapy may be due to genetic factors

FRIDAY, July 25 (HealthDay News) -- A new study challenges the long-held belief that the hepatitis C virus (HCV) impairs the immune system's ability to restore itself after HIV patients are treated with highly active antiretroviral therapy (HAART).

From 50 percent to 90 percent of HIV-infected drug users are also infected with HCV. Intravenous drug use is the main cause of both types of infection.

Researchers at Wake Forest University Baptist Medical Center focused on levels of CD4 cells -- the immune cells that are attacked by HIV -- and whether CD4 cells can rebuild after HAART is used to suppress HIV infection. For the study, the researchers analyzed the medical records of 322 patients.

"We've been observing that in some patients that are co-infected with hepatitis C, we were treating their HIV with HAART but didn't always get very good restoration of CD4," lead researcher Dr. Marina Nunez, an assistant professor of infectious diseases, said in a Wake Forest news release. "Some studies have suggested it was because of the hepatitis C. This study says it's not the presence of active hepatitis C replication."

She said impaired immune restoration seen in some HIV/HCV-infected patients after HAART may be due to a number of other causes, such as genetic factors involved in immune system regulation, confounding factors associated with HCV acquisition, or other unknown factors.

"Research efforts should pursue the role of those other factors in the immune restoration," Nunez said.

"From a clinical standpoint, although these findings will not alter the clinical management of HIV-HCV-co-infected patients, they make clear that even after successful treatment of the HCV infection, some patients may not get an adequate CD4 recovery under HIV treatment," she said.

The study was published in the July issue of AIDS Research and Human Retroviruses.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.

-- Robert Preidt

SOURCE: Wake Forest University Baptist Medical Center, news release, July 25, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: